SafeBridge has developed a new 1.5 hour webinar to provide staff working in pharmaceutical companies and contract manufacturers (CMOs) on the potent compound safety aspects of handling of antibody-drug-conjugates (ADCs). The webinar will cover key aspects of these compounds and their growing therapeutic use for cancer and other indications. Worker protection aspects of handling ADCs are critical as the “D” of the ADC are some of the most potent active pharmaceutical ingredients in the industry. Topics covered will include: Occupational health hazard assessment of the components of ADCs and the ADC itself, Occupational Exposure Limits (OELs) for ADCs, facility design, engineering controls,controls for synthesis, conjugation, fill/finish, dosage prep and laboratories,work practices, and the importance of applying the systematic and scientific approach including quantitative assessment using sensitive industrial hygiene analytical methods for verifying controls employed.
Who should attend: From lab and operations staff to management of drug innovators, CMOs, CDMOs and CROs handling ADCs; EHS and engineers responsible for ADC potent compound safety, CMC and project team members of ADC drug innovators
Discounts for multiple staff from the same company are available.
Contact: Kent Rader at kent.rader@safebridgefor further information and for group discounts.